直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
Dr. Antje Brambrink
Partner
More
vCard
  • Thierschplatz 6
  • 80538 Munich, Germany
+49 89 83931 1239
antje.brambrink@finnegan.com antje.brambrink@finnegan.com

Dr. Antje Brambrink

Partner

  • +49 89 83931 1239 +49 89 83931 1239
  • antje.brambrink@finnegan.com antje.brambrink@finnegan.com
  • Thierschplatz 6
  • 80538 Munich, Germany
  • vCard

Dr. Antje Brambrink ist als Rechtsanwältin in unserem Münchner Büro tätig. Sie berät und vertritt Mandanten in komplexen Patentstreitigkeiten zu allen Fragen des gewerblichen Rechtsschutzes, häufig an der Schnittstelle zum Kartell- und öffentlichen Recht. Ihre Expertise umfasst verschiedene Technologiebereiche, mit dem Schwerpunkt Pharmazeutika, Biotechnologie, Medizintechnik, erneuerbaren Energien und High Tech, wobei sie sich aufgrund ihrer Doppelqualifikation als Zahnärztin durch spezielle Expertise im Life Sciences Sektor auszeichnet.

Als Prozessanwältin vertritt Frau Dr. Brambrink Mandanten in multinationalen Patentstreitigkeiten sowohl in Verletzungs-, einstweiligen Verfügungs- und Besichtigungsverfahren vor deutschen Land- und Oberlandesgerichten als auch in Nichtigkeits- und Zwangslizenzverfahren vor dem Bundespatentgericht und dem Bundesgerichtshof.

Neben ihrer Tätigkeit als Prozessanwältin berät Frau Dr. Brambrink Mandanten strategisch zu allen Fragen im Zusammenhang mit gewerblichen Schutzrechten, wie z.B. der Vertragsgestaltung bei der Lizenzierung und Übertragung von Schutzrechten (Patente, Gebrauchsmuster, Ergänzende Schutzzertifikate) und zwar auch im Zusammenhang mit internationalen Transaktionen oder des neu eingerichteten Einheitlichen Patentgerichts (UPC). Besondere Erfahrung besitzt sie in der europaweiten Koordinierung von multinationalen Patentstreitigkeiten.

Vor ihrem Eintritt in unsere Sozietät war Frau Dr. Brambrink mehrere Jahre in zwei internationalen Kanzleien in Deutschland als Anwältin im Bereich Patentrecht tätig. Ihr medizinisch-naturwissenschaftlicher Hintergrund kommt Frau Dr. Brambrink bei der Beratung von Mandanten aus dem Bereich Life Sciences sehr zugute. Unternehmen aus der Pharma-, Biotechnologie und Medizinproduktebranche suchen daher regelmäßig ihren Rat. Daneben berät sie im Bereich erneuerbarer Energien sowie bei der Durchsetzung von standardessentiellen Patenten.

Frau Dr. Brambrink ist Autorin zahlreicher Veröffentlichungen in deutschen Fachzeitschriften. Intellectual Asset Management’s Strategy 300 hat Frau Dr. Brambrink als „Global Leader 2023“ ausgezeichnet.

Et Cetera

  • Author. “New decisions in Europe and the US in CRISPR/Cas9 patent dispute”, Comment on EPO and US decisions, Blog post, March 2022.
  • Coauthor. “German Federal Constitutional Court paves the way for the UPC”, Comment on the decision of the Federal Constitutional of 23 June 2021 (2 BvR 2216/20; 2 BvR 2217/20) Blog post, July 2021.
  • Author. “Eilanträge gegen Zustimmungsgesetz zum Abkommen über ein Einheitliches Patentgericht zurückgewiesen” (“Interim relief sought against the Act Approving the Agreement on a Unified Patent Court dismissed”), Comment on the order of the Federal Constitutional Court of 23/06/2021 – 2 BvR 2216/20, 2 BvR 2217/20 in GRUR-Prax 2021, 489.
  • Author. “UK-Unternehmen nach Brexit im Patentnichtigkeitsverfahren nicht von Prozesskostensicherheit befreit” (“No exemption for UK companies to provide security for legal costs in patent security proceedings after Brexit”), Comment on the order of the Federal Patent Court of 15/03/2021 – 3 Ni 20/20, in GRUR-Prax 2021, 413.
  • Author. “BGH klärt Anforderungen an neuheitsschädliche Vorwegnahme der Erfindung” (“Federal Supreme Court clarifies requirements for anticipation of invention detrimental to novelty”), Comment on the judgment of the Federal Supreme Court of 06/04/2021 - X ZR 54/19 in GRUR-Prax 2021, 377.
  • Author. “Zur Prozesskostensicherheit nach Brexit auch in höherer Instanz” (“Security for legal costs to be provided post-Brexit, also in higher instances”), Comment on the order of the Federal Supreme Court of 01/03/2021 - X ZR 54/19 (BPatG) in GRUR-Prax 2021, 257.
  • Author. “Kartellrechtliche Anforderungen an den SEP-Inhaber bei (komplexen) Wertschöpfungsketten” (“Antitrust requirements for the SEP holder in (complex) value chains”), Comment on the order of the Regional Court of Duesseldorf of 26/11/2020 - 4c O 17/19 in GRUR-Prax 2021, 81.
  • Author. “FRAND-Einwand des Herstellers und seiner Zulieferer” (“FRAND objection by the manufacturer and its suppliers”), Comment on the judgment of the Regional Court of Mannheim of 18/08/2020 - 2 O 34/19 in GRUR-Prax 2020, 513.
  • Author. “Gesetz zum Abkommen über Einheitliches Patentgericht ist nichtig” (“Law on the Unified Patent Court Agreement is and void”), Comment on the order of the Federal Constitutional Court of 13/02/2020 - 2 BvR 739/17 in GRUR-Prax 2020, 184.
  • Author. “BGH konkretisiert Bewertungsmaßstab für erfinderische Tätigkeit bei allgemein verfügbaren Werkzeugen” (“Federal Supreme Court specifies assessment standard for inventive step in case of generally available tools”), Comment on the judgment of the Federal Supreme Court of 17/12/2019 - X ZR 115/17 in GRUR-Prax 2020, 235.

Experience

Coordinated a European patent dispute on pharmaceuticals*

Provided a renowned globally acting pharmaceutical company with strategic advice on the coordination of a patent dispute with generics in several European jurisdictions.

Represented a company in compulsory license proceedings*

Advised and represented a pharmaceutical company in compulsory license proceedings before the Federal Patent Court.

BPatG

Represented a medical devices company before German Civil Courts and the European Patent Office (EPO)*

Advised and represented a medical devices company as the plaintiff in infringement proceedings and together with a patent attorney in the defense in opposition proceedings before the European Patent Office (EPO).

German Civil Patent Courts
EPO

Represented a pharmaceutical company before German Civil Patent Courts*

Advised and represented a market leading pharmaceutical company in defending its blockbuster products for cancer treatment against generics in Germany based on a large patent and segregated portfolio company (SPC).

German Civil Patent Courts

Represented a pharmaceutical originator before German Civil Patent Courts*

Advised and represented a globally acting pharmaceutical company to protect an orphan drug against generic competition.

German Civil Patent Courts

Represented a renewable energy company in infringement and nullity proceedings*

Advised and represented a company in the renewable energies sector in nullity proceedings before the Federal Patent Court and the Federal Supreme Court as well as in parallel infringement proceedings before the German Civil Courts.

German Civil Patent Courts
BPatG
BGH

More

Insights

Webinar

Implementation of Long-Arm Jurisdiction by the UPC Court and German National Courts: Strategic Considerations and Practical Implications Implementation of Long-Arm Jurisdiction by the UPC Court and German National Courts: Strategic Considerations and Practical Implications

May 12, 2026

Webinar

Panel Discussion

Global Patent Strategies & Litigation: An Exclusive Off-the-Record Conversation with Experienced In-House Leaders Global Patent Strategies & Litigation: An Exclusive Off-the-Record Conversation with Experienced In-House Leaders

May 5, 2026

London

Seminar

The Doctrine of Equivalents at the UPC

The Doctrine of Equivalents at the UPC The Doctrine of Equivalents at the UPC

April 16, 2026

Munich

Conference

2026 FCBA Global Series Spring Session 2026 FCBA Global Series Spring Session

April 8, 2026

Washington, DC

Articles

The UPC - Only Three Years Old and Already Leading

The UPC - Only Three Years Old and Already Leading The UPC - Only Three Years Old and Already Leading

March 18, 2026

Intellectual Asset Management (IAM)

Articles

SEP Licensing In Europe: Recent Developments

SEP Licensing In Europe: Recent Developments SEP Licensing In Europe: Recent Developments

March 5, 2026

LES Insights
More

News

Award/Ranking

Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked

May 28, 2026

Intellectual Asset Management (IAM)

Award/Ranking

Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award

May 13, 2026

Women in Business Law

Award/Ranking

Seven Finnegan Partners Named to IAM Strategy 300 Global Leaders 2026

Seven Finnegan Partners Named to IAM Strategy 300 Global Leaders 2026

November 19, 2025

Intellectual Asset Management (IAM)

Award/Ranking

Seven Finnegan Attorneys Named to the 2025 IAM Strategy 300 List Seven Finnegan Attorneys Named to the 2025 IAM Strategy 300 List

August 13, 2025

Intellectual Asset Management (IAM)

Award/Ranking

Best Lawyers in Germany Recognizes Four Finnegan Partners in Recent Rankings

Best Lawyers in Germany Recognizes Four Finnegan Partners in Recent Rankings

June 12, 2025

Best Lawyers

Award/Ranking

50 Finnegan Attorneys Ranked in the 2025 IAM Patent 1000

50 Finnegan Attorneys Ranked in the 2025 IAM Patent 1000

June 2, 2025

Intellectual Asset Management (IAM)
More

Professional Activities

  • Deutsche Vereinigung für gewerblichen Rechtsschutz und Urheberrecht e.V. (GRUR)
  • ChIPs Network Inc.’s (ChIPs)
  • Bayerische Landeszahnärztekammer (BLZK)
Admissions and Education

Admissions

  • Zugelassen als Rechtsanwältin für die Vertretung vor allen deutschen Amts-, Landes- und Oberlandesgerichten sowie in Nichtigkeitsverfahren vor dem Bundespatentgericht und dem Bundesgerichtshof

Education

Oberlandesgericht Hamm
Law Certificate, Zweites Staatsexamen Rechtswissenschaften, 2016
Westfälische Wilhelms-Universität Münster
Law Certificate, Erstes Staatsexamen Rechtswissenschaften, 2014
Leuphana Universität Lüneburg
M.B.A., Management of Ambulatory and Integrated Medical Health Care Systems, 2004
Privatuniversität Witten/Herdecke
Dissertation (Ph.D.), School of Dental, Oral and Maxillofacial Medicine, Major Pharmacology, 2003
Privatuniversität Witten/Herdecke
Dental Certificate, Staatsexamen, Zahnärztliche Prüfung, Approbation, 1998

Languages

  • Englisch
  • Deutsch

Antje's Practices

AI + Finnegan
AI + Patent
AI + Trade Secrets
Appeals, Issues, and Legal Strategy
Patent Oppositions and Appeals
Diligence, Licensing, and Opinions
Due Diligence
Licensing, Pooling, and Other Transactions
Opinions and Counseling
Patent Mining and Mapping
Standard Essential Patents (SEPs)
Global IP Enforcement, Litigation, and Trials
Antitrust and Misuse
Due Diligence
Patent Litigation and Trials
Pretrial Strategies
Standard Essential Patents (SEPs)
Trade Secrets
Unitary Patent System (UPS) and the Unified Patent Court (UPC)
Patent Office Invalidation Proceedings
Nullity Actions
Patent Oppositions and Appeals
Third-Party Observations
Prosecution and Portfolio Management
IP Portfolio Management
Patent Term Extension (PTE) and Supplementary Protection Certificate (SPC)
Standard Essential Patents (SEPs)
Trade Secrets

Antje's Industries

AI, Electronics, and Information Technology
Artificial Intelligence (AI) and Machine Learning (ML)
Electrical and Computer Technology
Electronic Devices and Components
Robotics
Chemicals, Industrials, and Materials
Additive Manufacturing
Chemical
Manufacturing
Textiles
Communications
Financial Services and Business Systems
Internet of Things (IoT)
Consumer Goods and Services
Food and Beverage
Energy
Clean Energy and Renewables
Hospitality, Gaming, and Leisure
Sports, Fitness, and Outdoor Recreation
Life Sciences
Biologics
Biotechnology
Digital Health
Medical Device and Diagnostics
Pharmaceutical
Transportation and Logistics
Automotive and Smart Mobility Tech

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP